Hanmi Science (008930) Stock Price, Fundamentals & Analysis

What 008930 does

Hanmi Science (008930) is a Healthcare stock in the Medical Distribution industry listed on the Korea Exchange. Through its subsidiaries, it manufactures and sells pharmaceutical products in Korea and internationally, developing drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment, and provides automated drug management systems, selling its products through online and offline pharmacies. Formerly known as Hanmi Holdings Co., Ltd., it changed its name in March 2012 and was founded in 1973, with headquarters in Seoul, South Korea. In the Korean healthcare space, it is sometimes compared with peers such as Hanall Biopharma (009420), Chong Kun Dang (185750), and SK Bioscience (302440).

Key numbers explained

• Price: The current trading price of 52,100 KRW is the last executed transaction amount per share.
• Market cap: At 3.53T KRW, the market capitalization represents the total value of all outstanding shares, calculated as share price multiplied by shares outstanding.
• Price change today: A move of +2.76% shows the percentage gain from the previous day's closing price to the current session.
• Dividend yield: The 0.58% dividend yield is the annual dividend per share divided by the current price, indicating the cash return relative to the share price.
• Ex-dividend date: Mar 30, 2026 is the date on or after which a buyer is no longer entitled to the upcoming dividend payment.
• Share of earnings paid out as dividends: 13% of earnings are distributed as dividends, meaning the company retains the majority for reinvestment.
• Beta: A 0.49 beta suggests the stock has historically moved about half as much as the overall market in percentage terms, indicating lower volatility relative to the market.
• 52-week range: The lowest and highest prices in the last 52 weeks were 25,600 and 61,000 KRW, showing the trading range over the past year.
• Price change over the last 52 weeks: A 34.5% increase from one year ago to the current price reflects the total return from price movement over that period.
• Revenue, trailing 12 months: 1.41T KRW is the sum of revenue over the last four quarters, providing a recent annual sales figure.
• Revenue growth, year over year: 8.7% shows the percentage increase in trailing 12-month revenue compared to the same period one year earlier.
• Profit margin: 10.7% means the company keeps 10.7 cents of net profit for every 100 KRW of revenue.
• Operating margin: 5.8% reflects operating profit as a percentage of revenue, showing earnings from core operations before interest and taxes.
• Return on equity: 15.5% return on equity measures how much net income the company generates for each unit of shareholder equity.
• Debt-to-equity ratio: 17.3% indicates that for every 100 units of equity, the company has 17.3 units of debt, a measure of financial leverage.

What to watch

Investors tracking Hanmi Science (008930) may monitor factors common to Healthcare and Medical Distribution stocks. Regulatory changes in Korea or international markets can affect drug approvals and distribution margins. Research and development outcomes for diabetes and anti-cancer pipelines may influence long-term growth expectations. Currency movements between the Korean won and other currencies can affect reported results for international operations. Competitive dynamics with peers such as Daewoong Pharmaceutical (069620), Daewoong (003090), and Green Cross (006280) may impact market share and pricing. Broader macroeconomic conditions, including interest rates and healthcare spending trends, can also influence the sector. For those building a diversified portfolio, the stock's inclusion in indices such as the KOSPI 200 is one factor to consider.